ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
  • ʲôڹУδҽ

    ᣬһBRAFƼBRAF V600EͻĺɫߡǼ̵¡޷ƥ֮׼ĵֺɫҩһMEKƼ׼BRAF V600E/KͻںɫߡBRAFһԭ򡣴Լ8%BRAFͻ䡣ͻBRAF V600Eͻ䣬Ҫںɫ״ٰͽ᳦ͻ䵼MEK/ERKźͨ·ijֳϮתҪһ׶/ڶ׶ʾϼʹӦʱһ

  • ķʱ䣬ҩô

    һֿڷġѪƤ(VEGFR)123ǿЧ͸ѡҰἤøƼ̹ᡢҩԸǿܹѪչ20121FDA׼Ŀǰڰŷˡձйڵ81һ׼20154»йʳҩ֣CFDA׼ڼܹһҰἤøƼϸʧܵĽչϸRCCij˻ߡЧã(Ӣ)mRCCҪﵽ

  • ˾AlpelisibӦ֢ح÷حעحӦ˵

    ӢͨAlpelisibͨ˾ӢƷPIQRAY͹Ƭ50mg;150mg;200mg顿2019524գFDA׼alpelisib˾PIQRAYNovartis Pharmaceuticals Corporationά˾ȺڣͨFDA׼IJԼ⵽Ƽ壨HRԣ˱Ƥ2HER2ԣPIK3CAͻ䣬ŮԵڻתٰڷڵķ֮չİ֢˾ƷPiqrayһּøƼά˾ȺƾһڷΪķڼ

  • ˾ٰЧΣʹעЩ

    2019524գFDA׼alpelisib˾PIQRAYNovartis Pharmaceuticals Corporationά˾ȺڣͨFDA׼IJԼ⵽Ƽ壨HRԣ˱Ƥ2HER2ԣPIK3CAͻ䣬ŮԵڻתٰڷڵķ֮չİ֢˾ƷPiqrayһּøƼά˾ȺƾһڷΪķڼƺչģϲ壨HRԡ˱Ƥ2HER2ԡPIK3CAͻڻתԻŮٰ

  • ҩʲôҩҩô

    ᣨCabozantinibһ໯ðеֱMETVEGFR1VEGFR 2VEGFR 3ROS1RETAXLNTRKKITо֤ƶҰἤøĻԣRET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, TIE-2ЩҰἤøϸܺͲ̣תƣѪɣҩԺ΢ά֡ͨöӦĻе㣬ѪɣϸǨƺϸֳ; ƻѪ; ٴǰģյϸ

  • ѳЧãйҽ

    ѳȫŮ԰֢ĵڰ˴󳣼ԭ򣬴Լ22%ѳBRCA1/2ͻ䡣ȫеĵһPARPƼ4఩֢ѳٰٰǰٰ߸Ӧ֢1һάBRCAmѳ˻ߣ2ϱһάͬԴȱݣHRDѳ˻ߣ3άƸѳ˻ߣ4gBRCAmѳ˻ߣ5gBRCAmHER2ԣHER2-תٰ˻ߣ6һάgBRCAmתٰ

  • ᣫƸΣIIIںɫ5޸ʸ

    գԺɫ̱3COMBI-ADоĽѷڡӢҽѧ־NEJMʾڸΣIIIBRAFͻԺɫУгɫʹðƷTafinlardabrafenibMekinisttrametinibƣṩڡ־õ޸棨RFS洦һϣ52%Ļ5ڴ޸COMBI-ADǵһ֤ƷڸƸΣIIIBRAFͻɫʾ5޸о밲οȣTafinlar+MekinistϿɽս49%Tafin

  • ḨEGFRm СϸΰЧͰȫΣ

    գ2020ŷҽѧѧᣨESMOAstraZeneca˰򿹰ҩosimertinibϣIIIADAURAо̽ԷԽʾѽȫгڣIB/II/IIIAڣƤͻ䣨EGFRmСϸΰNSCLCУʾϵͳCNS޲ڣDFSٴĸơǿѱ֤ʵİCNSתٴЧϹԤָ밲οȣḨƵĻָ߳¼٣11% vs 46%

  • ӦƤ׻ŷCHMPƼ׼

    ӦƤףADһص֢ƤҪΪҵԵʪƤòӤ׶ֻԸʪƤ˯ȱʧʳԼӰӰ컼ߵգŷҩƷ֣EMAҽҩƷίԱᣨCHMPѷһݻƼ׼ڷJAKƼOlumiantbaricitinibᣩʺϵͳƵжضӦƤףAD˻ߡһÿտڷһεѡԡJAK1JAK2ƼĿǰ

  • PiqrayPIK3CAͻHR+/HER2-ٰӳڣ

    ȫΧڣÿ33.4˱ΪٰaBCԼ40%HR+/HER2-ͻߴPIK3CAͻ䣬ͻ̼Ӧ𲻼ѡԤܲءҩPiqrayһ֦PI3KøƼҲΨһһר׼ЯPIK3CAͻٰߵƷȺŷ׼ƾŮԺٰߣΪڷƷƺչЯPIK3CAͻ䡢HR+/HER2-ֲڻתٰߡգ2020ŷҽѧѧᣨESMOŵٰPiqr

  • ͻҽҩڷ

    ڷNETԴϵͳ໥õϸص壬ԴںܶಿλβΪԻڷͨΪڷͷڷͻҽҩᣨsurufatinib2ҩѻйҩƷලڷһ͵ĿڷҰἤøƼпѪɺߵ˫ػԡҩͨѪƤ壨VEGFRͳάϸ壨FGFRѪɣƼ

  • 鵥ٰΣַҩ

    PATRICIAһǰհԵġűǩġII飬ļܹ2-4ԿHER2ΪķƵٰߡ200 mg/գ2ܣͣ1ܣ鵥ơоǻһ3еSimon׶ƣƼ壨ERԣAУERԣB1УER+B2УERԻ߱B1лB2СҪյ6ʱ޽չʣPFS6ҪյȫԺPAM50͵ļ71λߣA 15λB1B2и28λAB1B2еPFS6ֱΪ3

  • NMPAôʾصѪϸܰ֯ϸ֢зС׷

    20206£ôƣڽܰصƷΪMabCampathƵBϸܰϸѪ(B-CLL)УʱIJӦ棬Ѫϸܰ֯ϸ֢HLHз(ȱѪԺͳѪз)СסصƷΪMabCampathļôƷ˵Ѹ£޸ĺİȫϢصƷΪMabCampathһֵ¡壬֮ǰδƵĽB-CLLߵƣMabCampathҲƺͷʧܵB-CLLߵơ201910£ô

  • PD-1ƷحOpdivoȵYervoyƶĤƤ

    գŷҩƷ֣EMAPD-1ƷOpdivoŷ֣ͨnivolumabȵϿCTLA-4ƷYervoyipilimumabķ꣩һƶĤƤMPMII룬˴α룬õ˹ؼIIICheckMate-743о֧֡оʾоﵽҪյ㣺뻯ȣOpdivo+YervoyOSƣλLS18.1 vs 14.1£ս26%HR=0.7496.6%CI:0.60-0.91p=0.0022Opdivo+Yervoy黼ߴΪ41%Ϊ27%ĤƤMPMһֺ

  • ̹۸LYSODREN̹Ӧ֢˵

    ̹(Mitotane)Bristol-Myers Squibb޷ġԺͷǹƤʰƤԼµƤʴ֢ƵЧҩ̹Mitotane͹ЧΪ34%61%λ67¡ԹƤʰʹƤʹ֢ܿ״⣬Сӳ۸񡿣ʱʩ󱦹˾-500mg100Ƭ/С1150 ԪLYSODREN(̹,Mitotane)˵顡Ӧ֢1.ԲгԶתƵƤʰЧ͹ЧΪ34%61%λ67£2.Թ

  • оಡԤ󣬶оڹҽ

    SGLT2ƼཱུҩJardianceŷƾ®empagliflozinоͨʸйһμļͨಡĻߣͲ򲡣Ԥ˥סԺա֮ǰFDAо2ͨʸ񣺡120196£˥ߣCHFߵѪ˥סԺա220203£ͰಡCKD˻ߵ༲չѪաͨʸFTDּڼؼҩ↑Ϳ飬Խؼδҽʵ

  • magrolimabƹ쳣ۺ֢ܻʸߴ92%

    գFDAmagrolimabͻҩʸBTDϵĹ쳣ۺMDSMDSһɹγɲʧѪϸİ֢magrolimabһЩѪҺѧʵн˿MDS֮ǰmagrolimabѱFDAMDSϵѪAMLԴBϸܰDLBCLܰFLĿͨʸFTD2020ŷѪҺѧѧᣨEHSϹʾmagrolimab밢ƵĿߣn=33У͹ۻʣORRߴ91%ȫ

  • ĤйУҽ

    հݶBayerŷҩƷ֣EMA׼Eylea®ͨafliberceptעҺµԤʽעҺ5ֳĤEyleaһͲעVEGFƼһںϵףѪƤϸӣVEFG12İ򵰰G1ĿɽᾧƬں϶ɡEyleaΪVEGFԱVEGF-ḀӣPIGFһֿն巢ãЩӾмߵ׺ӶЩͬԴVEGFĽϣEylea쳣Ѫ

  • ǰٰӳ

    CARDоУ밢³ȣŸǰܶۼźŰƼƵתȥƵֿǰٰߵ޽չںڡCARDһģűǩ4о漰13ŷ޹ҵ62ٴԻΪ18ȷתȥƵֿǰٰߣ1:1飨25mg/m2Σ3һΣǿɣ10mg/պϸ̼ӣ vs 飨1000mg/+ǿ 5 mg2/գ³飨160mg/գڷҪյ޽չڡ20151117

  • ҩحDupixentʳٴЧô

    գŵԪFDAͿҩDupixentƷףͨȵdupilumabͻҩʸBTDơ12ʳףEoEߡĿǰFDA׼EoEҩEoEһԺͽ2֢Լʳֹʱƣȵ2֢ᵼʳۺխʹѡƣEoEӰ컼ߵĽʳʳʺסʳǶӶҽƼȡ˴BTDDupixentEoEߵһؼIII

共有173页首页上一页123456789下一页尾页
客服中心
联系方式
400-001-9763
- ѯ
ɨάѯ